Export 92 results:
Author Title [ Type(Desc)] Year
Filters: Author is Pedro Rosa-Neto  [Clear All Filters]
Journal Article
Milella MS, Marengo L, Larcher K, Fotros A, Dagher A, Rosa-Neto P, Benkelfat C, Leyton M.  2014.  Limbic system mGluR5 availability in cocaine dependent subjects: a high-resolution PET [(11)C]ABP688 study.. Neuroimage. 98:195-202.
Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER et al..  2019.  Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.. Alzheimers Dement. 15(6):742-753.
Kim D, Kim RGyung, Kim H-S, Kim J-M, Jun SChan, Lee B, Jo HJoon, Rosa-Neto P, Lee M-C, Kim H-I.  2015.  Longitudinal changes in resting-state brain activity in a capsular infarct model.. J Cereb Blood Flow Metab. 35(1):11-9.
DuBois JM, Rousset OG, Guiot M-C, Hall JA, Reader AJ, Soucy J-P, Rosa-Neto P, Kobayashi E.  2016.  Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging.. Cereb Cortex.
Smart K, Nagano-Saito A, Milella MS, Sakae DYae, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P et al..  2020.  Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans.. J Psychiatry Neurosci. 45(4):190162.
Zimmer ER, Parent MJ, A Cuello C, Gauthier S, Rosa-Neto P.  2014.  MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research.. Trends Neurosci. 37(11):629-41.
Ng KPin, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MSu, Shin M, Guiot M-C, Guo Q, Harada R, Comley RA et al..  2017.  Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain.. Alzheimers Res Ther. 9(1):25.
Binette APichet, Gonneaud J, Vogel JW, La Joie R, Rosa-Neto P, D Collins L, Poirier J, Breitner JCS, Villeneuve S, Vachon-Presseau E.  2020.  Morphometric network differences in ageing versus Alzheimer's disease dementia.. Brain. 143(2):635-649.
Parent MJ, Zimmer ER, Shin M, Kang MSu, Fonov VS, Mathieu A, Aliaga A, Kostikov A, Carmo SDo, Dea D et al..  2017.  Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.. J Neurosci. 37(50):12263-12271.
Ng KPin, Pascoal TA, Mathotaarachchi S, Chung C-O, Benedet AL, Shin M, Kang MSu, Li X, Ba M, Kandiah N et al..  2017.  Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 88(19):1814-1821.
Meyer P-F, Labonte A, Rosa-Neto P, Poirier J, Breitner JCS.  2019.  No apparent effect of naproxen on CSF markers of innate immune activation.. Ann Clin Transl Neurol. 6(6):1127-1133.
Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C et al..  2019.  Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease.. Nat Commun. 10(1):4227.
Lafaille-Magnan M-E, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS.  2017.  Odor identification as a biomarker of preclinical AD in older adults at risk.. Neurology. 89(4):327-335.
Gauthier S, Herrmann N, Rosa-Neto P.  2018.  Optimal use of cholinergic drugs in Alzheimer's disease.. Brain.
Cyr M, Parent MJ, Mechawar N, Rosa-Neto P, Soucy J-P, Aliaga A, Kostikov A, Maclaren DAA, Clark SD, Bedard M-A.  2014.  PET imaging with [¹⁸F]fluoroethoxybenzovesamicol ([¹⁸F]FEOBV) following selective lesion of cholinergic pedunculopontine tegmental neurons in rat.. Nucl Med Biol. 41(1):96-101.
Zukotynski K, Kuo PH, Mikulis D, Rosa-Neto P, Strafella AP, Subramaniam RM, Black SE.  2018.  PET/CT of Dementia.. AJR Am J Roentgenol. 211(2):246-259.
Ba M, Li X, Ng KPin, Pascoal TA, Mathotaarachchi S, Rosa-Neto P, Gauthier S.  2017.  The prevalence and biomarkers' characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database.. Alzheimers Dement (N Y). 3(1):107-113.
Turgeon M, Oualkacha K, Ciampi A, Miftah H, Dehghan G, Zanke BW, Benedet AL, Rosa-Neto P, Greenwood CMt, Labbe A.  2016.  Principal component of explained variance: An efficient and optimal data dimension reduction framework for association studies.. Stat Methods Med Res.
Villeneuve S, Vogel JW, Gonneaud J, Binette APichet, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS et al..  2018.  Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.. JAMA Neurol.
Schirrmacher R, Bailey JJ, Mossine AV, Scott PJH, Kaiser L, Bartenstein P, Lindner S, Kaplan DR, Kostikov A, Fricker G et al..  2019.  Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging.. Pharmaceuticals (Basel). 12(1)
Ng KPin, Therriault J, Kang MSu, Struyfs H, Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Massarweh G, Soucy J-P et al..  2019.  Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [F]THK5351 uptake in progressive supranuclear palsy.. Neuroimage Clin. 24:102091.
Kim H-S, Kim D, Kim RGyung, Kim J-M, Chung E, Rosa-Neto P, Lee M-C, Kim H-I.  2014.  A rat model of photothrombotic capsular infarct with a marked motor deficit: a behavioral, histologic, and microPET study.. J Cereb Blood Flow Metab. 34(4):683-9.
Guadagno A, Kang MSu, Devenyi GA, Mathieu AP, Rosa-Neto P, Chakravarty MM, C-D Walker.  2018.  Reduced resting-state functional connectivity of the basolateral amygdala to the medial prefrontal cortex in preweaning rats exposed to chronic early-life stress.. Brain Struct Funct.
Schilling LPorcello, Pascoal TA, Zimmer ER, Mathotaarachchi S, Shin M, Rieder CRoberto de, Gauthier S, Palmini A, Rosa-Neto P.  2018.  Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia.. Mol Neurobiol.
Tardif CL, Devenyi GA, Amaral RSC, Pelleieux S, Poirier J, Rosa-Neto P, Breitner JCS, Chakravarty MM.  2018.  Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.. Hum Brain Mapp. 39(2):971-984.